Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Sarcoma 1Plasma cell 1Lymphoid 1CNS 1

Conditions

Multiple Myeloma 232Lymphoma 46Lymphoma, Mantle-Cell 44Neoplasms, Plasma Cell 40Recurrence 30Lymphoma, Non-Hodgkin 29Lymphoma, Follicular 26Leukemia, Myeloid, Acute 25Lymphoma, Large B-Cell, Diffuse 22Waldenstrom Macroglobulinemia 21Precursor Cell Lymphoblastic Leukemia-Lymphoma 20Lymphoma, B-Cell, Marginal Zone 19Leukemia, Lymphocytic, Chronic, B-Cell 19Carcinoma, Non-Small-Cell Lung 18Leukemia 15Hodgkin Disease 13Neoplasms 12Immunoglobulin Light-chain Amyloidosis 12Hematologic Neoplasms 11Unspecified Adult Solid Tumor, Protocol Specific 9Myelodysplastic Syndromes 9Lymphoma, B-Cell 9Burkitt Lymphoma 9Lymphoma, Large-Cell, Immunoblastic 8Lymphoma, Large-Cell, Anaplastic 8Head and Neck Neoplasms 8Congenital Abnormalities 8Breast Neoplasms 8Sarcoma 7Lymphoma, Extranodal NK-T-Cell 7

Interventions

Vincristine 10Filgrastim 10Cyclophosphamide 10Doxorubicin 8Etoposide 7Radiotherapy 6Dactinomycin 6Carboplatin 6Granulocyte Colony-Stimulating Factor 5Topotecan 4Polymerase Chain Reaction 4Gene Expression Profiling 4sargramostim 3Temozolomide 3Reverse Transcriptase Polymerase Chain Reaction 3Peripheral Blood Stem Cell Transplantation 3Melphalan 3Itraconazole 3Irinotecan 3Ifosfamide 3DNA Methylation 3Cisplatin 3Busulfan 3liposomal amphotericin B 2ixabepilone 2X-Rays 2Voriconazole 2Therapeutics 2Stem Cell Transplantation 2Specimen Handling 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Wilms Tumor × Bortezomib × Clear all
NCT01827137 2024-09-19

WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation

Sellas Life Sciences Group

Phase 1/2 Completed
20 enrolled 9 charts
GenitourinaryPlasma cell

Multiple Myeloma, Wilms Tumor

NCT01132911 2017-07-02

A Phase I Study of Vorinostat and Bortezomib in Children With Refractory of Recurrent Solid Tumors, Including CNS Tumors and Lymphomas

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
5 enrolled
CNSGenitourinaryLymphoidSarcoma

Lymphoma, Neoplasms, Wilms Tumor, Neuroblastoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡